![Talha Badar: CRh as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia](https://oncodaily.com/pub/uploads/2024/07/Screenshot-2024-07-15-205707.png)
Jul 15, 2024, 13:21
Talha Badar: CRh as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia
Talha Badar shared on X:
Pooled analysis of IDH1/2i and FLT3i in clinical trails, suggest CRh meaningful endpoint in improving outcome with non-myelosuppressive therapies.
Authors: Robert Q. LeDonna PrzepiorkaHaiyan ChenYuan Li ShenE. Dianne PulteKelly NorsworthyMarc R. TheoretR. Angelo De Claro.”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.